Fundamental scientific research and discovery are the primary activity of the Rappaport Institute. There is also an important appreciation that this discovery process can yield applications of translational and applicable utility, as well as commercial value. The latter constitutes the basis for the Rappaport Institute's intellectual property assets. Since one of the stated goals of the Rappaport Institute, is to develop a financial basis for fueling its continued primary mission of fundamental research discovery, BioRap Technologies was established to identify and to leverage research innovation towards potential commercialization. BioRap Technologies, in conjunction with the Technion Research and Development Foundation, and in partnership with other technology transfer offices of collaborating institutions, provides the full spectrum of support for the identification and protection of biomedical research based intellectual property, with translation to commercial applications. The first Chief Executive Officer of BioRap Technologies, Mr. David Promof, was instrumental in shaping the foundation of the BioRap Technologies enterprise. At present Dr. Orit Shaked is the Chief Executive Officer of BioRap Technologies.